Mark is a healthcare executive with more than 20 years of experience. He has a wide range of focus both on the clinical and commercial sides of the business within the rare diseases, Neurology, urology, pain, primary care, infectious disease and dental industries. Mark currently serves on the Board of Directors and Executive Committee of the Epilepsy Foundation.
Most recently, Mark served as Executive Vice President and Chief Operating Officer of Engage Therapeutics. Engage Therapeutics was in the process of developing Staccato® Alprazolam and if approved will be the first and only drug-device-combination for the rapid termination of an active epileptic seizure. Engage was sold to UCB in 2020 in a deal valued at $270 million following the successful completion of its randomized, phase 2b clinical study.
Previously, Mark served as Vice President of Sales, Trade and Commercial Operations at Egalet. As one of the first commercial employees, Mark was integral in establishing key functions within Trade, Commercial Operations and Sales Excellence at Egalet in order to lead the launch of three products within the company’s first two years. Prior to that, he was an Executive Director of Decision Support and member of the U.S. Commercial Leadership team at NPS until it was acquired by Shire plc in 2015. Before this role at NPS, Mark headed up Sales Operations at ViroPharma until it was acquired by Shire plc in 2014.
Mark started his career as a sales representative at Alza, which was acquired by Johnson & Johnson in 2001. Over the next 10 years, Mark held a number of sales, training, operations and analytics positions of increasing responsibility within the Johnson & Johnson family of companies.